Mechanisms underlying prostate cancer sensitivity to reactive oxygen species: overcoming radiotherapy resistance and recent clinical advances

References

1. 1.↵
   2. Siegel RL,
   3. Giaquinto AN,
   4. Jemal A.

   Cancer statistics, 2024. CA Cancer J Clin. 2024; 74: 12–49.

   OpenUrlCrossRefPubMed
2. 2.↵
   2. Hoge C,
   3. Sidana A.

   Multidisciplinary clinics: a possible means to help to eliminate racial disparities in prostate cancer. Cancer. 2020; 126: 2938–9.

   OpenUrlPubMed
3. 3.↵
   2. Baskar R,
   3. Lee KA,
   4. Yeo R,
   5. Yeoh K-W.

   Cancer and radiation therapy: current advances and future directions. Int J Med Sci. 2012; 9: 193–9.

   OpenUrlCrossRefPubMed
4. 4.↵
   2. Hu M,
   3. Wang L,
   4. Su D,
   5. Yuan Q,
   6. Xiao C,
   7. Guo L, et al.

   Evaluation of mycotoxins, mycobiota and toxigenic fungi in the traditional medicine Radix Dipsaci. Front Microbiol. 2024; 15: 1454683.
5. 5.↵
   2. Parker CC,
   3. Kynaston H,
   4. Cook AD,
   5. Clarke NW,
   6. Catton CN,
   7. Cross WR, et al.

   Duration of androgen deprivation therapy with postoperative radiotherapy for prostate cancer: a comparison of long-course versus short-course androgen deprivation therapy in the RADICALS-HD randomised trial. Lancet. 2024; 403: 2416–25.

   OpenUrlPubMed
6. 6.↵
   2. Habib TN,
   3. Altonsy MO,
   4. Ghanem SA,
   5. Salama MS,
   6. Hosny MA.

   Optimizing combination therapy in prostate cancer: mechanistic insights into the synergistic effects of Paclitaxel and sulforaphane-induced apoptosis. BMC Mol Cell Biol. 2024; 25: 5.

   OpenUrlPubMed
7. 7.↵
   2. Wang L,
   3. Luo R,
   4. Onyshchenko K,
   5. Rao X,
   6. Wang M,
   7. Menz B, et al.

   Adding liposomal doxorubicin enhances the abscopal effect induced by radiation/αPD1 therapy depending on tumor cell mitochondrial DNA and cGAS/STING. J Immunother Cancer. 2023; 11: e006235.
8. 8.↵
   2. Rao X,
   3. Onyshchenko K,
   4. Wang L,
   5. Wang M,
   6. Niedermann G.

   Comparison of two triple therapy regimens for enhancing the abscopal effect in mice. Int J Radiat Oncol Biol Phys. 2023; 117: e256.
9. 9.↵
   2. Wang M,
   3. Rao X,
   4. Gaedicke S,
   5. Wang L,
   6. Menz B,
   7. Multhoff G, et al.

   Adding a PPARα agonist enhances T cell-mediated effects of RT in combination with anti-PD-1. Int J Radiat Oncol Biol Phys. 2024; 120: e409–10.

   OpenUrl
10. 10.↵
    2. Koka K,
    3. Verma A,
    4. Dwarakanath BS,
    5. Papineni RV.

    Technological advancements in external beam radiation therapy (EBRT): an indispensable tool for cancer treatment. Cancer Manag Res. 2022; 14: 1421–9.

    OpenUrlPubMed
11. 11.↵
    2. Taylor A,
    3. Powell ME.

    Intensity-modulated radiotherapy – what is it? Cancer Imaging. 2004; 4: 68–73.

    OpenUrlCrossRefPubMed
12. 12.
    2. Correa RJM,
    3. Loblaw A.

    Stereotactic body radiotherapy: hitting harder, faster, and smarter in high-risk prostate cancer. Front Oncol. 2022; 12: 889132.
13. 13.↵
    2. Tsang DS,
    3. Patel S.

    Proton beam therapy for cancer. CMAJ. 2019; 191: E664–6.

    OpenUrlFREE Full Text
14. 14.↵
    2. Matsumoto Y,
    3. Fukumitsu N,
    4. Ishikawa H,
    5. Nakai K,
    6. Sakurai H.

    A critical review of radiation therapy: from particle beam therapy (proton, carbon, and BNCT) to beyond. J Pers Med. 2021; 11: 825.

    OpenUrlPubMed
15. 15.↵
    2. Hu J,
    3. Pan M,
    4. Wang Y,
    5. Zhu Y,
    6. Wang M.

    Functional plasticity of neutrophils after low- or high-dose irradiation in cancer treatment – a mini review. Front Immunol. 2023; 14: 1169670.
16. 16.↵
    2. Xing R,
    3. Wang M,
    4. Wang L,
    5. Pan M,
    6. Wang Y,
    7. Zhou H.

    Clinical updates of B-cell maturation antigen-targeted therapy in multiple myeloma (MM) and relapsed/refractory MM (Review). Int J Mol Med. 2024; 55: 27.

    OpenUrlPubMed
17. 17.↵
    2. Rui X,
    3. Meidan W,
    4. Gongqiang W,
    5. Longyi Z,
    6. Xiaoxia W,
    7. Wei C, et al.

    Chemotherapy-induced toxic epidermal necrolysis in a patient with multiple myeloma, a case report and literature review. Front Oncol. 2023; 13: 1227448.
18. 18.↵
    2. Chargari C,
    3. Deutsch E,
    4. Blanchard P,
    5. Gouy S,
    6. Martelli H,
    7. Guérin F, et al.

    Brachytherapy: an overview for clinicians. CA Cancer J Clin. 2019; 69: 386–401.

    OpenUrlCrossRefPubMed
19. 19.↵
    2. Donovan JL,
    3. Hamdy FC,
    4. Lane JA,
    5. Mason M,
    6. Metcalfe C,
    7. Walsh E, et al.

    Patient-reported outcomes after monitoring, surgery, or radiotherapy for prostate cancer. N Engl J Med. 2016; 375: 1425–37.

    OpenUrlCrossRefPubMed
20. 20.↵
    2. Zaorsky NG,
    3. Davis BJ,
    4. Nguyen PL,
    5. Showalter TN,
    6. Hoskin PJ,
    7. Yoshioka Y, et al.

    The evolution of brachytherapy for prostate cancer. Nat Rev Urol. 2017; 14: 415–39.

    OpenUrlPubMed
21. 21.↵
    2. Perillo B,
    3. Di Donato M,
    4. Pezone A,
    5. Di Zazzo E,
    6. Giovannelli P,
    7. Galasso G, et al.

    ROS in cancer therapy: the bright side of the moon. Exp Mol Med. 2020; 52: 192–203.

    OpenUrlCrossRefPubMed
22. 22.↵
    2. Nogueira V,
    3. Patra KC,
    4. Hay N.

    Selective eradication of cancer displaying hyperactive Akt by exploiting the metabolic consequences of Akt activation. ELife. 2018; 7: e32213.
23. 23.↵
    2. Hamid AA,
    3. Gray KP,
    4. Shaw G,
    5. MacConaill LE,
    6. Evan C,
    7. Bernard B, et al.

    Compound genomic alterations of TP53, PTEN, and RB1 tumor suppressors in localized and metastatic prostate cancer. Eur Urol. 2019; 76: 89–97.

    OpenUrlPubMed
24. 24.↵
    2. Gong Y,
    3. Chippada-Venkata U,
    4. Oh W.

    Roles of matrix metalloproteinases and their natural inhibitors in prostate cancer progression. Cancers (Basel). 2014; 6: 1298–327.

    OpenUrlPubMed
25. 25.↵
    2. Kumar B,
    3. Koul S,
    4. Khandrika L,
    5. Meacham RB,
    6. Koul HK.

    Oxidative stress is inherent in prostate cancer cells and is required for aggressive phenotype. Cancer Res. 2008; 68: 1777–85.

    OpenUrlAbstract/FREE Full Text
26. 26.↵
    2. Arfin S,
    3. Jha NK,
    4. Jha SK,
    5. Kesari KK,
    6. Ruokolainen J,
    7. Roychoudhury S, et al.

    Oxidative stress in cancer cell metabolism. Antioxidants. 2021; 10: 642.

    OpenUrlPubMed
27. 27.↵
    2. Nakano H,
    3. Nakajima A,
    4. Sakon-Komazawa S,
    5. Piao JH,
    6. Xue X,
    7. Okumura K.

    Reactive oxygen species mediate crosstalk between NF-kappaB and JNK. Cell Death Differ. 2006; 13: 730–7.

    OpenUrlCrossRefPubMedWeb of Science
28. 28.↵
    2. Woodbine L,
    3. Brunton H,
    4. Goodarzi AA,
    5. Shibata A,
    6. Jeggo PA.

    Endogenously induced DNA double strand breaks arise in heterochromatic DNA regions and require ataxia telangiectasia mutated and Artemis for their repair. Nucleic Acids Res. 2011; 39: 6986–97.

    OpenUrlCrossRefPubMedWeb of Science
29. 29.↵
    2. Luo H,
    3. Liu Y,
    4. Li Y,
    5. Zhang C,
    6. Yu B,
    7. Shao C.

    Androgen receptor splicing variant 7 (ARv7) promotes DNA damage response in prostate cancer cells. FASEB J. 2022; 36: e22495.
30. 30.↵
    2. Lyu F,
    3. Shang SY,
    4. Gao XS,
    5. Ma MW,
    6. Xie M,
    7. Ren XY, et al.

    Uncovering the secrets of prostate cancer’s radiotherapy resistance: advances in mechanism research. Biomedicines. 2023; 11: 1628.

    OpenUrlPubMed
31. 31.↵
    2. Rivlin N,
    3. Brosh R,
    4. Oren M,
    5. Rotter V.

    Mutations in the p53 tumor suppressor gene: important milestones at the various steps of tumorigenesis. Genes Cancer. 2011; 2: 466–74.

    OpenUrlCrossRefPubMed
32. 32.
    2. Jamaspishvili T,
    3. Berman DM,
    4. Ross AE,
    5. Scher HI,
    6. De Marzo AM,
    7. Squire JA, et al.

    Clinical implications of PTEN loss in prostate cancer. Nat Rev Urol. 2018; 15: 222–34.

    OpenUrlCrossRefPubMed
33. 33.↵
    2. Liu X,
    3. Fan L,
    4. Lu C,
    5. Yin S,
    6. Hu H.

    Functional role of p53 in the regulation of chemical-induced oxidative stress. Oxid Med Cell Longev. 2020; 2020: 6039769.
34. 34.↵
    2. Shah R,
    3. Ibis B,
    4. Kashyap M,
    5. Boussiotis VA.

    The role of ROS in tumor infiltrating immune cells and cancer immunotherapy. Metabolism. 2024; 151: 155747.
35. 35.↵
    2. An X,
    3. Yu W,
    4. Liu J,
    5. Tang D,
    6. Yang L,
    7. Chen X.

    Oxidative cell death in cancer: mechanisms and therapeutic opportunities. Cell Death Dis. 2024; 15: 556.

    OpenUrlPubMed
36. 36.↵
    2. Liu R,
    3. Bian Y,
    4. Liu L,
    5. Liu L,
    6. Liu X,
    7. Ma S.

    Molecular pathways associated with oxidative stress and their potential applications in radiotherapy. Int J Mol Med. 2022; 49: 65.

    OpenUrlPubMed
37. 37.↵
    2. Huang R,
    3. Chen H,
    4. Liang J,
    5. Li Y,
    6. Yang J,
    7. Luo C, et al.

    Dual role of reactive oxygen species and their application in cancer therapy. J Cancer. 2021; 12: 5543–61.

    OpenUrlCrossRefPubMed
38. 38.↵
    2. Zhao Z,
    3. Liu P,
    4. Zhang H,
    5. Wang M,
    6. Liu Y,
    7. Wang L, et al.

    Gastrodin prevents stress-induced synaptic plasticity impairment and behavioral dysfunction via cAMP/PKA/CREB signaling pathway. Phytomedicine. 2025; 141: 156661.
39. 39.↵
    2. Nyberg T,
    3. Frost D,
    4. Barrowdale D,
    5. Evans DG,
    6. Bancroft E,
    7. Adlard J, et al.

    Prostate cancer risks for male BRCA1 and BRCA2 mutation carriers: a prospective cohort study. Eur Urol. 2020; 77: 24–35.

    OpenUrlCrossRefPubMed
40. 40.↵
    2. Fiorentino M,
    3. Judson G,
    4. Penney K,
    5. Flavin R,
    6. Stark J,
    7. Fiore C, et al.

    Immunohistochemical expression of BRCA1 and lethal prostate cancer. Cancer Res. 2010; 70: 3136–9.

    OpenUrlAbstract/FREE Full Text
41. 41.↵
    2. Kung Y-A,
    3. Chiang HJ,
    4. Li ML,
    5. Gong YN,
    6. Chiu HP,
    7. Hung CT, et al.

    Acyl-coenzyme a synthetase long-Chain family member 4 is involved in viral replication organelle formation and facilitates virus replication via ferroptosis. mBio. 2022; 13: e02717–21.

    OpenUrlCrossRefPubMed
42. 42.↵
    2. Chen H,
    3. Lyu F,
    4. Gao X.

    Advances in ferroptosis for castration-resistant prostate cancer treatment: novel drug targets and combination therapy strategies. Prostate Cancer Prostatic Dis. 2024. doi:10.1038/s41391-024-00933-w.

    OpenUrlCrossRef
43. 43.↵
    2. Wang M-E,
    3. Chen J,
    4. Lu Y,
    5. Bawcom AR,
    6. Wu J,
    7. Ou J, et al.

    RB1-deficient prostate tumor growth and metastasis are vulnerable to ferroptosis induction via the E2F/ACSL4 axis. J Clin Invest. 2023; 133: e166647.
44. 44.↵
    2. Han C,
    3. Wang Z,
    4. Xu Y,
    5. Chen S,
    6. Han Y,
    7. Li L, et al.

    Roles of reactive oxygen species in biological behaviors of prostate cancer. BioMed Res Int. 2020; 2020: 1269624.
45. 45.↵
    2. Yamamori T,
    3. Yasui H,
    4. Yamazumi M,
    5. Wada Y,
    6. Nakamura Y,
    7. Nakamura H, et al.

    Ionizing radiation induces mitochondrial reactive oxygen species production accompanied by upregulation of mitochondrial electron transport chain function and mitochondrial content under control of the cell cycle checkpoint. Free Radic Biol Med. 2012; 53: 260–70.

    OpenUrlCrossRefPubMed
46. 46.↵
    2. Westhaver LP,
    3. Nersesian S,
    4. Nelson A,
    5. MacLean LK,
    6. Carter EB,
    7. Rowter D, et al.

    Mitochondrial damage-associated molecular patterns trigger arginase-dependent lymphocyte immunoregulation. Cell Rep. 2022; 39: 110847.
47. 47.↵
    2. Raymakers L,
    3. Demmers TJ,
    4. Meijer GJ,
    5. Molenaar IQ,
    6. van Santvoort HC,
    7. Intven MPW, et al.

    The effect of radiation treatment of solid tumors on neutrophil infiltration and function: a systematic review. Int J Radiat Oncol Biol Phys. 2024; 120: 845–61.

    OpenUrlCrossRefPubMed
48. 48.↵
    2. Bae T,
    3. Hallis SP,
    4. Kwak M-K.

    Hypoxia, oxidative stress, and the interplay of HIFs and NRF2 signaling in cancer. Exp Mol Med. 2024; 56: 501–14.

    OpenUrlCrossRefPubMed
49. 49.↵
    2. Mohamed OAA,
    3. Tesen HS,
    4. Hany M,
    5. Sherif A,
    6. Abdelwahab MM,
    7. Elnaggar MH.

    The role of hypoxia on prostate cancer progression and metastasis. Mol Biol Rep. 2023; 50: 3873–84.

    OpenUrlPubMed
50. 50.↵
    2. Valikhani M,
    3. Rahimian E,
    4. Ahmadi SE,
    5. Chegeni R,
    6. Safa M.

    Involvement of classic and alternative non-homologous end joining pathways in hematologic malignancies: targeting strategies for treatment. Exp Hematol Oncol. 2021; 10: 51.

    OpenUrlPubMed
51. 51.↵
    2. Stangelberger A,
    3. Waldert M,
    4. Djavan B.

    Prostate cancer in elderly men. Rev Urol. 2008; 10: 111–9.

    OpenUrlPubMed
52. 52.↵
    2. Diehn M,
    3. Cho RW,
    4. Lobo NA,
    5. Kalisky T,
    6. Dorie MJ,
    7. Kulp AN, et al.

    Association of reactive oxygen species levels and radioresistance in cancer stem cells. Nature. 2009; 458: 780–3.

    OpenUrlCrossRefPubMedWeb of Science
53. 53.↵
    2. Xu Y,
    3. Fang F,
    4. St Clair DK,
    5. St Clair WH.

    Inverse relationship between PSA and IL-8 in prostate cancer: an insight into a NF-κB-mediated mechanism. PLoS One. 2012; 7: e32905.
54. 54.↵
    2. DeNicola GM,
    3. Karreth FA,
    4. Humpton TJ,
    5. Gopinathan A,
    6. Wei C,
    7. Frese K, et al.

    Oncogene-induced Nrf2 transcription promotes ROS detoxification and tumorigenesis. Nature. 2011; 475: 106–9.

    OpenUrlCrossRefPubMedWeb of Science
55. 55.↵
    2. Bellezza I,
    3. Scarpelli P,
    4. Pizzo SV,
    5. Grottelli S,
    6. Costanzi E,
    7. Minelli A.

    ROS-independent Nrf2 activation in prostate cancer. Oncotarget. 2017; 8: 67506–18.

    OpenUrlCrossRefPubMed
56. 56.↵
    2. Smolková K,
    3. Mikó E,
    4. Kovács T,
    5. Leguina-Ruzzi A,
    6. Sipos A,
    7. Bai P.

    Nuclear factor erythroid 2-related factor 2 in regulating cancer metabolism. Antioxid Redox Signal. 2020; 33: 966–97.

    OpenUrlPubMed
57. 57.↵
    2. Zhang P,
    3. Singh A,
    4. Yegnasubramanian S,
    5. Esopi D,
    6. Kombairaju P,
    7. Bodas M, et al.

    Loss of Kelch-like ECH-associated protein 1 function in prostate cancer cells causes chemoresistance and radioresistance and promotes tumor growth. Mol Cancer Ther. 2010; 9: 336–46.

    OpenUrlAbstract/FREE Full Text
58. 58.↵
    2. Ge W,
    3. Zhao K,
    4. Wang X,
    5. Li H,
    6. Yu M,
    7. He M, et al.

    iASPP is an antioxidative factor and drives cancer growth and drug resistance by competing with Nrf2 for Keap1 binding. Cancer Cell. 2017; 32: 561–73.e6.

    OpenUrlCrossRefPubMed
59. 59.↵
    2. Chen JY,
    3. Wang FB,
    4. Xu H,
    5. Xu LF,
    6. Chen D,
    7. Liu WH, et al.

    High glucose promotes prostate cancer cells apoptosis via Nrf2/ARE signaling pathway. Eur Rev Med Pharmacol Sci. 2019; 23: 192–200.

    OpenUrlPubMed
60. 60.↵
    2. Lin L,
    3. Wu Q,
    4. Lu F,
    5. Lei J,
    6. Zhou Y,
    7. Liu Y, et al.

    Nrf2 signaling pathway: current status and potential therapeutic targetable role in human cancers. Front. Oncol. 2023; 13: 1184079.
61. 61.↵
    2. Lin J,
    3. Zhang G,
    4. Lou B,
    5. Sun Y,
    6. Jia X,
    7. Wang M, et al.

    Identification of copper metabolism-related markers in Parkinson’s disease. Ann Med. 2024; 56: 2425064.
62. 62.↵
    2. El Bezawy R,
    3. Tripari M,
    4. Percio S,
    5. Cicchetti A,
    6. Tortoreto M,
    7. Stucchi C, et al.

    SPOP deregulation improves the radiation response of prostate cancer models by impairing DNA damage repair. Cancers. 2020; 12: 1462.

    OpenUrlPubMed
63. 63.↵
    2. Clark A,
    3. Burleson M.

    SPOP and cancer: a systematic review. Am J Cancer Res. 2020; 10: 704–26.

    OpenUrlPubMed
64. 64.↵
    2. Hernández-Llodrà S,
    3. Segalés L,
    4. Juanpere N,
    5. Marta Lorenzo T,
    6. Salido M,
    7. Nonell L, et al.

    SPOP and CHD1 alterations in prostate cancer: relationship with PTEN loss, tumor grade, perineural infiltration, and PSA recurrence. Prostate. 2021; 81: 1267–77.

    OpenUrlPubMed
65. 65.↵
    2. Rahmy S,
    3. Cheng X,
    4. Wang M,
    5. Feng H,
    6. Qiu W,
    7. Zhao R, et al.

    Organ-specific regulation of CHD1 by acute PTEN and p53 loss in mice. Biochem Biophys Res Commun. 2020; 525: 614–9.

    OpenUrlPubMed
66. 66.↵
    2. Geng C,
    3. Zhang MC,
    4. Manyam GC,
    5. Vykoukal JV,
    6. Fahrmann JF,
    7. Peng S, et al.

    SPOP mutations target STING1 signaling in prostate cancer and create therapeutic vulnerabilities to PARP inhibitor–induced growth suppression. Clin Cancer Res. 2023; 29: 4464–78.

    OpenUrlPubMed
67. 67.↵
    2. Xiao M,
    3. Fried JS,
    4. Ma J,
    5. Su Y,
    6. Boohaker RJ,
    7. Zeng Q, et al.

    A disease-relevant mutation of SPOP highlights functional significance of ATM-mediated DNA damage response. Sig Transduct Target Ther. 2021; 6: 17.

    OpenUrl
68. 68.↵
    2. Piombino C,
    3. Pipitone S,
    4. Tonni E,
    5. Mastrodomenico L,
    6. Oltrecolli M,
    7. Tchawa C, et al.

    Homologous recombination repair deficiency in metastatic prostate cancer: new therapeutic opportunities. Int J Mol Sci. 2024; 25: 4624.

    OpenUrlPubMed
69. 69.↵
    2. Kalkavan H,
    3. Green DR.

    MOMP, cell suicide as a BCL-2 family business. Cell Death Differ. 2018; 25: 46–55.

    OpenUrlCrossRefPubMed
70. 70.↵
    2. Kale J,
    3. Osterlund EJ,
    4. Andrews DW.

    BCL-2 family proteins: changing partners in the dance towards death. Cell Death Differ. 2018; 25: 65–80.

    OpenUrlCrossRefPubMed
71. 71.↵
    2. Liu P,
    3. Zhao Z,
    4. Zhang H,
    5. Xiao C,
    6. Wang M,
    7. Yang C, et al.

    A comprehensive pharmacology study reveals the molecular mechanisms underlying the antidepressant effects of Gastrodiae Rhizoma. Phytomedicine. 2025; 142: 156761.
72. 72.↵
    2. Xu H,
    3. Sun Y,
    4. Huang CP,
    5. You B,
    6. Ye D,
    7. Chang C.

    Preclinical study using ABT263 to increase enzalutamide sensitivity to suppress prostate cancer progression via targeting BCL2/ROS/USP26 axis through altering ARv7 protein degradation. Cancers. 2020; 12: 831.

    OpenUrlPubMed
73. 73.↵
    2. Zeitlin BD,
    3. Zeitlin IJ,
    4. Nör JE.

    Expanding circle of inhibition: small-molecule inhibitors of Bcl-2 as anticancer cell and antiangiogenic agents. J Clin Oncol. 2008; 26: 4180–8.

    OpenUrlAbstract/FREE Full Text
74. 74.↵
    2. An J,
    3. Chervin AS,
    4. Nie A,
    5. Ducoff HS,
    6. Huang Z.

    Overcoming the radioresistance of prostate cancer cells with a novel Bcl-2 inhibitor. Oncogene. 2007; 26: 652–61.

    OpenUrlCrossRefPubMed
75. 75.↵
    2. Sternberg CN,
    3. Dumez H,
    4. Van Poppel H,
    5. Skoneczna I,
    6. Sella A,
    7. Daugaard G, et al.

    Docetaxel plus oblimersen sodium (Bcl-2 antisense oligonucleotide): an EORTC multicenter, randomized phase II study in patients with castration-resistant prostate cancer. Ann Oncol. 2009; 20: 1264–9.

    OpenUrlCrossRefPubMedWeb of Science
76. 76.↵
    2. Stein MN,
    3. Hussain M,
    4. Stadler WM,
    5. Liu G,
    6. Tereshchenko IV,
    7. Goodin S, et al.

    A phase II study of AT-101 to overcome Bcl-2–mediated resistance to androgen deprivation therapy in patients with newly diagnosed castration-sensitive metastatic prostate cancer. Clin Genitourin Cancer. 2016; 14: 22–7.

    OpenUrlCrossRefPubMed
77. 77.↵
    2. Xu Z,
    3. Zhang Y,
    4. Dai H,
    5. Han B.

    Epithelial-mesenchymal transition-mediated tumor therapeutic resistance. Molecules. 2022; 27: 4750.

    OpenUrlPubMed
78. 78.↵
    2. Pastushenko I,
    3. Blanpain C.

    EMT transition states during tumor progression and metastasis. Trends Cell Biol. 2019; 29: 212–26.

    OpenUrlCrossRefPubMed
79. 79.↵
    2. Papanikolaou S,
    3. Vourda A,
    4. Syggelos S,
    5. Gyftopoulos K.

    Cell plasticity and prostate cancer: the role of epithelial–mesenchymal transition in tumor progression, invasion, metastasis and cancer therapy resistance. Cancers. 2021; 13: 2795.

    OpenUrlPubMed
80. 80.↵
    2. Iczkowski KA.

    Cell adhesion molecule CD44: its functional roles in prostate cancer. Am J Transl Res. 2010; 3: 1–7.

    OpenUrlPubMed
81. 81.↵
    2. Smith BN,
    3. Odero-Marah VA.

    The role of Snail in prostate cancer. Cell Adh Migr. 2012; 6: 433–41.

    OpenUrlCrossRefPubMed
82. 82.↵
    2. Shang Z,
    3. Cai Q,
    4. Zhang M,
    5. Zhu S,
    6. Ma Y,
    7. Sun L, et al.

    A switch from CD44⁺ cell to EMT cell drives the metastasis of prostate cancer. Oncotarget. 2015; 6: 1202–16.

    OpenUrlPubMed
83. 83.↵
    2. Stakheev D,
    3. Taborska P,
    4. Strizova Z,
    5. Podrazil M,
    6. Bartunkova J,
    7. Smrz D.

    The WNT/β-catenin signaling inhibitor XAV939 enhances the elimination of LNCaP and PC-3 prostate cancer cells by prostate cancer patient lymphocytes in vitro. Sci Rep. 2019; 9: 4761.

    OpenUrlPubMed
84. 84.↵
    2. Jannu M,
    3. Jinka R.

    Liquid biopsy: a non-invasive tool to detect cancer at an early stage. Int J Adv Res. 2023; 11: 234–50.

    OpenUrl
85. 85.↵
    2. Gogola S,
    3. Rejzer M,
    4. Bahmad HF,
    5. Abou-Kheir W,
    6. Omarzai Y,
    7. Poppiti R.

    Epithelial-to-mesenchymal transition-related markers in prostate cancer: from bench to bedside. Cancers (Basel). 2023; 15: 2309.

    OpenUrlPubMed
86. 86.↵
    2. Martín-Contreras M,
    3. Navarro-Marchal SA,
    4. Peula-García JM,
    5. Jódar-Reyes AB.

    Progress and hurdles of therapeutic nanosystems against cancer. Pharmaceutics. 2022; 14: 388.

    OpenUrlPubMed
87. 87.↵
    2. Castle J,
    3. Shaker H,
    4. Morris K,
    5. Tugwood JD,
    6. Kirwan CC.

    The significance of circulating tumour cells in breast cancer: a review. Breast. 2014; 23: 552–60.

    OpenUrlCrossRefPubMed
88. 88.↵
    2. Mulvey A,
    3. Muggeo-Bertin E,
    4. Berthold DR,
    5. Herrera FG.

    Overcoming immune resistance with radiation therapy in prostate cancer. Front Immunol. 2022; 13: 859785.
89. 89.↵
    2. Lo U-G,
    3. Lee C-F,
    4. Lee M-S,
    5. Hsieh J-T.

    The role and mechanism of epithelial-to-mesenchymal transition in prostate cancer progression. Int J Mol Sci. 2017; 18: 2079.

    OpenUrlPubMed
90. 90.↵
    2. Zhang H,
    3. Zhao Z,
    4. Liu P,
    5. Wang M,
    6. Liu Y,
    7. He H, et al.

    Gastrodin enhances stress resilience through promoting Wnt/β-Catenin-dependent neurogenesis. J Adv Res. 2025. doi:10.1016/j.jare.2025.04.017.

    OpenUrlCrossRef
91. 91.↵
    2. Borella R,
    3. Forti L,
    4. Gibellini L,
    5. De Gaetano A,
    6. De Biasi S,
    7. Nasi M, et al.

    Synthesis and anticancer activity of CDDO and CDDO-Me, two derivatives of natural triterpenoids. Molecules. 2019; 24: 4097.

    OpenUrlPubMed
92. 92.↵
    2. Zhang C,
    3. Su ZY,
    4. Khor TO,
    5. Shu L,
    6. Kong AN.

    Sulforaphane enhances Nrf2 expression in prostate cancer TRAMP C1 cells through epigenetic regulation. Biochem Pharmacol. 2013; 85: 1398–404.

    OpenUrlCrossRefPubMed